Kommentar zu: „Darmkrebs: PI3K-mutierte Tumoren rezidivieren mit Acetylsalicylsäure seltener“

• Literatur

• 1 Martling A, Myrberg IH, Nilbert M. et al. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N Engl J Med 2025; 393: 1051-1064
• 2 Güller U, Hayoz S, Horber D. et al. Adjuvant aspirin treatment in PIK3CAmutated colon cancer patients: the SAKK 41/13 prospective randomized placebocontrolled double-blind trial. Clin Cancer Res 2025; 31: 3142-3149
• 3 ASCOLT Investigators. Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers (ASCOLT): randomised trial. Lancet Oncol 2025; 26: 112-123
• 4 Bains SJ, Mahic M, Myklebust TÅ. et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol 2016; 34: 2501-2508